Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory syncytial virus
Biotech
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
Enanta’s zelicapavir reduced viral load in children, maintaining hopes the biotech can find a niche in a market dominated by Big Pharma vaccines.
James Waldron
Dec 9, 2024 9:35am
Pfizer lets its RSV pipeline dry up in crowded space
Oct 29, 2024 11:23am
Vicebio hauls in $100M series B to push RSV shot through phase 1
Sep 23, 2024 3:00am
Merck’s mAB prevents RSV in infants, teeing up talks with FDA
Jul 23, 2024 8:18am
Moderna's RSV shot efficacy wanes faster than GSK's Arexvy
Feb 9, 2024 2:44pm
Veru needs cash for fresh trial of respiratory distress drug
Feb 8, 2024 10:45am
